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Abstract
The Ca2 binding protein S100A1 increases the Ca2 release from the sarcoplasmatic reticulum by interacting with the
ryanodine receptor. In order to understand whether this effect might be operative in the early course of hypertrophy, when
myocardium is able to meet increased workload, we investigated the expression of S100A1 in a model of moderate right
ventricular hypertrophy. The pulmonary arteries of nine pigs were embolised three times with Sephadex G-50. After 70 days,
all pigs showed a moderate pulmonary hypertension. Right ventricular tissue of embolised animals showed a significant
increase of connective tissue and enlargement of myocyte diameters. In controls, we found a differential expression of
S100A1 with significantly lower S100A1 protein levels in right ventricular compared to left ventricular tissue. In pulmonary
hypertension, S100A1 expression increased significantly in hypertrophied right ventricles while it was unchanged in left
ventricular tissue. No change was observed in the expression of SERCA2a and phospholamban. Our data show, for the first
time, that moderate pressure overload results in an upregulation of S100A1. This may reflect an adaptive response of
myocardial Ca2 homeostasis to a higher workload. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The intracellular Ca2 cycling is largely deter-
mined by the activity of the sarcoplasmatic reticulum
(SR) [1]. Since Ca2 cycling is compromised in end
stage heart failure, studies have focussed on the func-
tional state of the SR in patients that underwent
cardiac transplantation [2]. Mulieri et al. [3] and
Pieske et al. [4] demonstrated a reversed force-fre-
quency relationship and an altered post-rest poten-
tiation in isolated muscle ¢bres, indicating a dysfunc-
tion of the SR in end stage heart failure. However,
the underlying molecular mechanisms are not fully
understood. Diminished systolic Ca2 peaks and in-
creased diastolic Ca2 levels [5,6] indicate an altered
activity of the sarcoplasmatic Ca2-release channel
(ryanodine receptor, RyR) and Ca2 ATPase (SER-
CA), respectively. An altered expression of SR pro-
teins has therefore been discussed as one of the pos-
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sible molecular causes of SR dysfunction. Results,
however, are still contradictory, possibly due to dif-
ferent methodological approaches [7,8].
Since the activity of RyR and SERCA are tightly
regulated [9], an altered regulation of Ca2 transients
might be due to SR dysfunction in end-stage heart
failure. It has been shown that Ca2 binding proteins
of the EF-hand type di¡erentially regulate SR Ca2
transients. Calmodulin is known to activate SERCA
via calmodulin kinase-dependent phosphorylation of
phospholamban [10] and it may also regulate the
activity of the ryanodine receptor (RyR) [11]. How-
ever, it is unknown whether calmodulin protein con-
centrations are altered in the human cardiomyo-
pathic heart since only mRNA data are available
[12].
Like calmodulin, S100 proteins also belong to the
large family of Ca2 binding proteins of the EF-hand
type. So far 19 S100 proteins have been discovered
which are involved in the regulation of cell di¡eren-
tiation, cell cycling, signal transduction and cyto-
skeletal architecture [13,14]. Due to their tissue spe-
ci¢c expression pattern, S100 proteins transduce the
ubiquitous Ca2 signal into cell-speci¢c signals by
hydrophobic interaction with speci¢c intracellular
target proteins. Among these proteins, the S100A1
protein displays a speci¢c expression in slow skeletal
and cardiac muscle and is involved in the activation
of the Ca2-induced Ca2 release [15].
The EF-hand type Ca2 binding protein S100A1 is
strongly associated with the SR [16] revealing a di-
rect protein interaction with the ryanodine receptor
[17] and possibly with the SERCA/phospholamban
complex, as has been proposed by Western blot over-
lay studies [18]. Due to this subcellular compartmen-
tation of S100A1 and its high expression level in
cardiac myocytes, we hypothesised that S100A1
might play a pivotal role in the cardiospeci¢c regu-
lation of SR function. While a regulation of the
SERCA/phospholamban complex by S100A1 still
appears hypothetical, S100A1 activates the Ca2 ac-
tivated Ca2 release in SR vesicle preparations [19]
and in permeabilised ¢bres [17]. Our ¢nding of a
signi¢cant downregulation of this protein in end-
stage heart failure [20] therefore may causally be re-
lated to a defective excitation^contraction coupling
as shown by Gomez et al. [21], who demonstrated
reduced Ca2 releases evoked by plasma membrane
Ca2 currents in failing myocardium. Data from
D’Agnolo et al. [22] who demonstrated a markedly
increased ca¡eine threshold in idiopathic dilated car-
diomyopathy would be in favour of this hypothesis.
If S100A1 protein levels indeed correlate with the
Ca2 release, an increased expression of this protein
should therefore be found in the setting of compen-
sated myocardial hypertrophy.
2. Materials and methods
The pulmonary arteries of nine male pigs were
embolised in three sessions each with 15 mg/kg
b.wt. Sephadex G-50. Haemodynamic measurements
were performed with a pulmonary artery catheter
after percutaneous catheterisation of the femoral
vein. The hearts of nine untreated animals served
as controls. Myocardial specimens were taken from
the free left-ventricular wall and the right-ventricular
outlet tract of embolised animals and untreated con-
trols after coronary perfusion of the hearts with 60
ml/kg b.wt. Eurocollins cardioplegic solution. The
present investigation represents a substudy of Wei-
mann et al. [23] and conforms with the Guide for the
Care and Use of Laboratory Animals published by
the US National Institute of Health (NIH Publica-
tion No. 85-23, revised 1996).
Five semithin sections of subendocardial tissue
blocks of each animal were evaluated according to
a systematic random embedding, random sectioning
and random sampling method [24]. Morphometric
measurements according to a point-counting method
were performed by light-microscopy as described by
Oberholzer et al. [25], using an ocular integrated test
system (Integrationsplatte, Zeiss, Oberkochen, Ger-
many). The volume densities of the endomysial con-
nective tissue indicating the state of ¢brosis were
evaluated at 100-fold magni¢cation on Ladewig-
stained sections [26]. The minimal myocyte diameters
at the cell nucleus level were evaluated at 1000-fold
magni¢cation on HE-stained sections and calculated
as mean value of 100 cross-sectioned myocytes using
a semi-automatic analysis system (Kontron, Eching,
Germany) and served as histological indicator for
myocyte hypertrophy [27].
Myocardial samples (100 mg) were homogenised in
5 vols. (v/w) of extraction bu¡er (25 mM Tris-HCl,
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50 mM KCl, 5 mM EDTA, 0.1 mM PMSF, pH 7.5)
and centrifuged (50 000Ug, 15 min). The protein
content of resultant supernatants were measured in
order to compare the total extractable protein
amounts from control and hypertrophied myocardi-
um using the DC Protein Assay (Bio-Rad, Hercules,
Ca, USA) as outlined by the manufacturer. The
supernatants were then adjusted to 1 mg/ml to opti-
mise ammonium sulfate (AS) precipitation and equi-
librated with AS (50% saturation) for 15 min at
room temperature. After centrifugation (50 000Ug,
15 min) the AS supernatants were injected onto an
Octyl-Sepharose column (Pharmacia, 1 ml) equili-
brated with loading bu¡er (25 mM Tris-HCl, 2 mM
CaCl2, pH 7.5). A step gradient was run with elution
bu¡er (25 mM Tris-HCl, pH 9.5, 5 mM EGTA,
pH 9.5). Eluting proteins were collected in aliquots
of 5 ml and then loaded onto an UnoQ-1 anion-ex-
changer (Bio-Rad) equilibrated with a low-salt bu¡er
(25mM Tris-HCl, pH 7.5). Proteins were eluted by a
linear gradient from 0 to 40% high-salt bu¡er (25 mM
Tris-HCl, 1 M NaCl, pH 7.5) within 40 min (£ow
rate 1 ml/min). UV monitoring was performed at
220 nm. Relative protein amounts were calculated
by peak integration. The S100A1 peak was identi¢ed
by Western blotting and electronspray-ionisation-
mass-spectrometry (ESI-MS) as described by Pedroc-
chi et al. [28].
For SDS-PAGE, the samples were homogenised in
urea bu¡er (50 mM Tris-HCl, 8 M urea, 5 mM
EGTA, pH 8.6) and centrifuged (50 000Ug, 15
min). The resulting supernatants were diluted 1:10
(v/v) in sample bu¡er (0.5 M Tris-HCl, 5% SDS,
10% glycerol, 0.05% Bromphenol blue, 5% L-mercap-
toethanol, pH 6.8) and boiled for 3 min. Ten-micro-
litre aliquots were separated on SDS-polyacrylamide
gels (15% T, 3% C) using the Tris-tricine bu¡er-sys-
tem [29]. The proteins were transferred to PVDF
sheets with a semi-dry transfer system [30]. The im-
munodetection of SERCA2a and phospholamban
was performed using the Western Light Plus-kit
(Tropix) employing the CSPD chemiluminescence ac-
cording to the manufacturer’s guidelines. Primary
antibodies (Biomol) were diluted 1:10 000 in block-
ing bu¡er, while the working dilution of the biotin-
labelled secondary antibody and the streptavidin^al-
kaline phosphatase conjugate was 1:20 000. Proteins
were quanti¢ed by densitometric peak integration.
Actin served as an internal standard for equivalent
protein load.
The mean values of integrated peaks of S100A1,
SERCA2a and phospholamban of left ventricular
controls was set 100%. Protein amounts are therefore
given as percent of control left ventricles þ standard
deviation (% þ S.D.). P-values were calculated by the
unpaired Student’s t-test.
3. Results
All pigs showed a moderate pulmonary hyperten-
sion after 70 days with three sessions of embolisa-
tions. Systolic pulmonary artery pressure increased
to 30.7 þ 4.3 mmHg (PAPmean 21 þ 5.5 mmHg) as
compared to controls 19 þ 0.6 mmHg (PAPmean
12 þ 0.4 mmHg) (Fig. 1). Right ventricular tissue of
embolised animals showed a signi¢cant increase of
myocyte diameters at cell nucleus level from 10.41 þ
1.40 to 12.89 þ 2.05 Wm (P6 0.01) (Fig. 2A,B).
Although perimysial connective tissue increased
from 1.12 þ 0.44% to 2.39 þ 0.94% (P6 0.001) the
total protein recovery from control and hypertro-
phied myocardial samples did not di¡er signi¢cantly
(2.86 þ 0.17 vs. 2.80 þ 0.23 g/l). Furthermore, no dif-
ference was seen in perimysial connective tissue
content and myocyte diameters of left ventricular
samples.
Since commercially available S100A1 antibodies
show a considerable crossreactivity with other S100
proteins, such as S100A4 and S100A6 (data not
Fig. 1. Haemodynamic measurements : systolic (PA sys) and
mean pulmonary pressures (PA mean) in embolised animals as
compared to controls. Bars are mean values with standard devi-
ation.
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shown), the quantitation of S100A1 in total tissue
extracts by Western blot analyses did not seem ap-
plicable. We therefore employed a combined HPLC
and mass spectrometry methodology to purify and
quantitate S100A1. After EDTA extraction of tissue
samples, the hydrophobic interaction chromatogra-
phy (HIC) resulted in an elution of mainly three
proteins that interacted in a calcium-dependent man-
ner with the octyl-Sepharose matrix (Fig. 4, lane 2).
These proteins were further fractionated by anion
exchanger chromatography UnoQ-1 (Fig. 3), reveal-
ing molecular masses of 66 734 Da (annexin VI),
10427 Da (S100A1), and 16 789 Da (calmodulin) as
detected by ESI-MS. The porcine S100A1 protein
peak revealed only one detectable mass (10 427
kDa) that correlated with the calculated molecular
mass of rat S100A1 (10 428 kDa). Western blotting
con¢rmed the presence of annexin VI (not shown),
S100A1 (Fig. 4B) and calmodulin (not shown), re-
spectively.
Quantitation of S100A1 by peak integration in
control animals revealed a di¡erential expression in
left and right ventricular tissues. Right ventricular
tissue of control animals showed signi¢cantly lower
Fig. 2. Histological analyses. (A) Connective tissue content in
PAH animals and controls in percent of volume density. (B)
Myocyte diameters at cell nucleus level in right ventricles of
embolised animals and controls in Wm.
Fig. 3. Elution pro¢le. Tissue extracts of 100 mg from UnoQ-1
anion exchanger (1.3 ml). Annexin VI (4 and 5), S100A1 (6),
and calmodulin (7) peaks as con¢rmed by Western blotting and
ESI-MS.
Fig. 4. Electrophoresis. (A) Silver stained SDS-PAGE and (B)
Western blot with monoclonal anti-S100A1 antibody (Sigma,
Munich) of protein peaks eluted from UnoQ-1 anion exchang-
er. Lane 1, EGTA tissue extract; lane 2, protein sample injected
on UnoQ-1; lanes 3^7, protein peaks eluted from UnoQ-1 as
numbered in Fig. 3. Protein standards: (A) Bio-Rad prestained
low (19^106 kDa) and (B) Tropix biotinylated MW markers
(6.5^200 kDa).
Fig. 5. S100A1 protein levels. Left (LV) and right ventricular
(RV) tissues of embolised animals and controls. The di¡erences
are highly signi¢cant between right ventricular tissues of embol-
ised and control animals (**P6 0.001). The di¡erential expres-
sion of S100A1 is signi¢cant between left and right ventricular
tissues of controls (*P6 0.01) while insigni¢cant in embolised
animals.
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relative protein levels of S100A1 amounting to
58 þ 21% compared to LV with 100 þ 31%
(P6 0.01). Embolised animals, however, showed a
signi¢cant increase of S100A1 levels in right ventric-
ular tissues with a relative amount of 122 þ 33% com-
pared to control right ventricular tissue (58 þ 21%;
P6 0.001). The signi¢cant di¡erence in S100A1 con-
centration between right and left ventricular tissue
was lost in the embolised animals (Fig. 5). Fig. 6
depicts the correlation of S100A1 protein expression
in right ventricular myocardium with the myocyte
diameter as found for control (open circles) and em-
bolised (¢lled squares) animals. While in both groups
S100A1 expression appears to be negatively corre-
lated with myocyte diameter, pressure overload of
the right ventricle leads to a signi¢cant increase of
S100A1 protein content for a given myocyte diame-
ter. In our experimental setting, we could not observe
any signi¢cant change in the expression of the SR
proteins SERCA2a and phospholamban (Fig. 7).
4. Discussion
Gwathmey et al. [2] showed, for the ¢rst time, that
intracellular Ca2 handling is abnormal in end-stage
heart failure re£ecting a defective SR function. Sev-
eral authors reported a decreased activity of SERCA
in end-stage heart failure using cell homogenates [31].
Highly puri¢ed membrane fractions of the sarcoplas-
matic reticulum, however, revealed an unchanged
stimulated SERCA activity in failing hearts as com-
pared to controls [32]. These con£icting results not
only re£ect di¡erent methodological approaches, but
also might indicate that factors regulating SERCA
activity, such as Ca2 binding proteins of the EF-
hand type, might be extracted during microsomal
preparations. If this hypothesis holds true, a di¡er-
ential expression of Ca2 binding proteins, that are
involved in the regulation of SR function, might ex-
plain di¡erential Ca2 handling by the SR in crude
homogenates and microsomal preparations of hyper-
trophied and failing hearts.
We chose a new model of repetitive pulmonary
embolism in order to mimic a gradual development
of right ventricular hypertrophy in pigs with a pre-
served systolic contractility [23]. All experimental an-
imals included showed criteria of compensated hy-
pertrophy with moderately increased systolic
pressures, signi¢cantly increased myocyte diameters
and concomitant ¢brosis while protein expression
levels of SERCA and phospholamban remained un-
a¡ected. As recently reported [20], we found a di¡er-
ential expression of S100A1 in control animals with
signi¢cantly higher protein levels in left ventricular
tissue as compared to the right ventricular and atrial
tissue. Interestingly, Minajeva et al. [33] found that
in ca¡eine-induced contracture, atrial ¢bres produce
a lower peak tension with a substantial tonic compo-
nent re£ecting a lower and slower Ca2 release from
SR than left ventricular ¢bres. Since S100A1 in-
creases the Ca2 release from the sarcoplasmatic re-
ticulum, a di¡erential expression of this Ca2 binding
protein might correlate with a di¡erential regulation
Fig. 6. S100A1 protein-expression and myocyte diameters: cor-
relation of S100A1 protein-expression with myocyte diameters
in control and embolised animals.
Fig. 7. SR proteins. Protein levels of phospholamban and SER-
CA2a in right and left ventricular tissues from embolised ani-
mals and controls as determined by Western blotting.
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of the ryanodine receptor in di¡erent areas of the
heart.
In the present study, pulmonary hypertension in-
duced a selective and signi¢cant increase of S100A1
protein expression in right ventricular tissues. Left
ventricular expression levels were una¡ected, insinu-
ating a locally controlled expression of S100A1. To
date, there are no data available as to the regulation
of S100A1 gene expression in mammals. Promoter
studies of the rat S100A1 gene [34], however, suggest
a possible mechanism for an upregulation of S100A1
in hypertrophy. Since the rat S100A1 promoter con-
tains several putative cAMP regulatory sequences on
a positive regulatory segment, a stimulation of the L-
adrenergic pathway [35] as found in early and com-
pensated myocardial hypertrophy, might induce
overexpression of the Ca2 binding protein
S100A1. The transition from compensated hypertro-
phy to heart failure in turn was reported to be corre-
lated with decreased cAMP levels [36] and thus
would explain the observed downregulation of
S100A1 in explanted myocardium from patients
with end-stage heart failure. Interestingly, S100A1
expression was negatively correlated with the myo-
cyte diameter both in the control and embolised ani-
mal group, while the latter group showed higher
S100A1 levels for a given myocyte diameter. The
molecular basis of this ¢nding is still unclear. Data
from Baudier et al. [37], however, show that S100A1
inhibits the phosphorylation of protein kinase C tar-
get proteins. Since the PKC pathway is involved in
the formation of cardiac hypertrophy [38], S100A1
might therefore also exert an antihypertrophic e¡ect.
Recently Tsutsui et al. [39] showed that an inhibition
of microtubule polymerisation by chronic colchicine
administration attenuates the progression of myocar-
dial hypertrophy in spontaneously hypertensive rats
independently of blood pressure. Since Donato [40]
documented an inhibition of microtuble polymerisa-
tion by S100A1, an increased expression of S100A1
might show an antihypertrophic e¡ect by modulating
the cytoskeleton.
In conclusion, our study shows for the ¢rst time
that the Ca2 binding protein S100A1 is di¡erentially
expressed in right and left ventricular myocardium,
revealing a signi¢cant upregulation upon pressure
overload after pulmonary artery embolisation. Since
S100A1 is involved in the regulation of the Ca2
release channel of the SR, a di¡erential expression
of S100A1 in di¡erent states of myocardial hyper-
trophy would be an attractive explanation for
changes in Ca2-handling found in the transition
from compensated hypertrophy to heart failure.
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